Toward synthetic biology with engineered T cells: A long journey just begun

Human Gene Therapy

Volumn 25, Issue 9, 2014, Pages 779-784

  June, Carl H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOLOGY; CELL ENGINEERING; HISTORY OF MEDICINE; IMMUNOCOMPETENT CELL; MEDICAL RESEARCH; REVIEW; SYNTHETIC BIOLOGY; T LYMPHOCYTE; CYTOLOGY; GENE THERAPY; GENETICS; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; PROCEDURES; TRENDS;

CELL ENGINEERING; GENETIC THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV; HUMANS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SYNTHETIC BIOLOGY; T-LYMPHOCYTES;

EID: 84907297480     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.2533     Document Type: Review

References (68)

1. Bernstein, W.B., Cox, J.H., Aronson, N.E., et al. (2004). Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4( + ) T cells to HIV-infected persons. Clin. Immunol. 111, 262-274.
2. Brentjens, R.J., Latouche, J.B., Santos, E., et al. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimula ted by CD80 and interleukin-15. Nat. Med. 9, 279-286.
3. Bretscher, P., and Cohn, M. (1970). A theory of self-nonself discrimination. Science 169, 1042-1049.
4. Cameron, B.J., Gerry, A .B., Dukes, J., et al. (2013). Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103.
5. Carpenito, C., Milone, M.C. , Hassan, R., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360-3365.
6. Carroll, R.G., Riley, J.L., Levine, B.L., et al. (1997). Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4 + T cells. Science 276, 273-276.
7. Cooper, L.J., Topp, M.S., Serrano, L.M., et al. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101, 1637-1644.
8. Deeks, S.G., Wagner, B., Anton, P.A., et al. (2002). A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination anti-retroviral therapy. Mol. Ther. 5, 788-797.
9. Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471.
10. Eshhar Z, Waks T , Gross G, Schindler DG. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. P roc. Natl. Acad. Sci. U S A 90, 720-724.
11. Frenkel, N., Schirmer, E.C., Katsafanas, G., and June, C.H. (1990a ). T-cell activation is required for efficient replication of human herpesvirus 6. J. Virol. 64, 4598-4602.
12. Frenkel, N., Schirmer, E.C., Wyatt, L.S., et al. (1990b ). Isolation of a new herpesvirus from human CD4 + T cells. Proc. Natl. Acad. Sci. USA 87, 748-752.
13. Friedmann, T . (1992). A brief history of gene therapy. Nat. Genet. 2, 93-98.
14. Friedmann T. and, Roblin, R., 1972, Gene therapy for human genetic disease? Science, 175, 949-955.
15. Gattinoni, L. , Lugli, E., Ji, Y., et al. (2011). A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297.
16. Gladwell, M. (2008). Outliers: The Story of Success. (Little, Brown and Company, New York, NY
17. Grupp, S.A., Kalos, M., Barrett, D., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
18. Irving, B.A., and Weiss, A. (1991). The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891-901.
19. June, C.H., and Rabinovitch, P .S. (1990). Flow cytometric measurement of intracellular ionized calcium in single cells with indo-1 and fluo-3. In Methods in Cell Biology. L. Wilson, ed. (Academic Press, Inc., San Diego, CA) pp. 37-58.
20. June , C.H., Contreras, C.E., Perrin, L.H., and Lambert, P.H. (1979a ). Improved detection of immune complexes in human and mouse serum using a microassay adaptation of the C1q binding test. J. Immunol. Methods 31, 23-29.
21. June, C.H., Contreras, C.E., Perrin, L.H., et al. (1979b ). Circulating and tissue-bound immune complex formation in murine malaria. J. Immunol. 122, 2154-2161.
22. June, C.H., Thompson, C.B., Kennedy, M.S., et al. (1985). Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation 39, 620-624.
23. June, C.H., Ledbetter, J.A., Rabinovitch, P.S., et al. (1986a ). Distinct patterns of transmembrane calcium flux and intracellular calcium mobilization after differentiation antigen cluster 2 (E rosette receptor) or 3 (T3) stimulation of human lymphocytes. J. Clin. Invest. 77, 1224-1232.
24. June, C.H., Thompson, C.B., Kennedy, M.S., et al. (1986b ). Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. Transplantation 41, 47-51.
25. June, C.H., Ledbetter, J.A., Gillespie, M.M., et al. (1987). Tcell proliferation involving the CD28 pathway is associated with cyc losporine-resistant interleukin 2 gene expression. Mol. Cell Biol. 7, 4472-4481.
26. June, C.H., Ledbetter, J.A., Lindsten, T., and Thompson, C.B. (1989). Evidence for the involvement of three distinct signals i n the induction of IL-2 gene expression in human T lymphocytes. J. Immunol. 143, 153-161.
27. June, C.H., Ledbetter, J.A., Linsley, P.S., and Thompson, C.B. (1990). Role of the CD28 receptor in T-cell activation. Immunol. Today 11, 211-216.
28. June, C.H., Linette, G.P., Pierce, P.F., et al. (1993). Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infecti on. Ann. N.Y. Acad. Sci. 677, 225-232.
29. Kalos, M., Levine, B.L., Porter, D.L., et al. (2011). T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia . Sci. Transl. Med. 3, 95ra73.
30. Kohn, D.B. (2007). Lentiviral vectors ready for prime-time. Nat. Biotechnol. 25, 65-66.
31. Laport, G.G., Levine, B.L., Stadtmauer, E.A., et al. (2003). Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34 +-selected hematopoietic cell transplantation. Blood 102, 2004-2013.
32. Ledbetter, J .A.,Gentry, L.E., June,C.H., et al. (1987).Stimulation ofT cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60 c-src in the activation pathway. Mol. Cell Biol . 7, 650-656.
33. Letourneur, F., and Klausner, R.D. (1991). T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA 88, 8905-8909.
34. Letourneur, F., and Klausner, R.D. (1991). T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc. Natl. Acad. Sci. USA 88, 8905-8909. Levine, B.L., Mosca, J., Riley, J.L., et al. (1996). Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-1943.
35. Levine, B.L., Bernstein, W., Craighead, N., et al. (1997). Effects of CD28 costimulation on long term proliferation of CD4 + T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921-5930.
36. Levine, B.L., Cotte, J., Small, C.C., et al. (1998). Large scale production of CD4 + T cells from HIV-infected donors following CD3/CD28 stimulation. J. Hematother. 7, 437-448.
37. Levine, B.L., Bernstein, W.B., Aronson, N.E., et al. (2002). Adoptive transfer of costimulated CD4 + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8, 47-53.
38. Levin e, B.L., Humeau, L.M., Boyer, J., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103, 17372-17377.
39. Linette,G.P.,Hartzman,R.J., Ledbette r, J.A., and June,C.H. (1988). HIV-1-infected T cells show a selective signaling defect after perturbation of CD3/antigen receptor. Science 241, 573-576.
40. Linette, G.P., Stadtmauer, E.A., Maus, M.V., et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122, 863-871.
41. Liu, K., Schoonmaker, M.M., Levine, B.L., et al. (1999). Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl. Acad. Sci. USA 96, 5147-5152.
42. Martin, P.J., Ledbetter, J.A., Morishita, Y., et al. (1986). A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol. 136, 3282-3287.
43. Maude, S., Frey, N., Shaw, P., et al. (2014). Sustained remissions with chimeric antigen receptor T cells for leukemia. N. Engl. J. Med. In press.
44. Maus, M.V., Thomas, A.K., Leonard, D.G., et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the Tcell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20, 143-148.
45. Maus, M.V., Kovacs, B., Kwok, W.W., et al. (2004). Extensive replicative capacity of human central memory T cells. J. Immunol. 172, 6675-6683.
46. Maus, M.V., Grupp, S.A., Porter, D.L., and June, C.H. (2014). Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635.
47. Milone, M.C., Fish, J.D., Carpenito, C., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464.
48. Mitsuyasu, R.T., Anton, P., Deeks, S.G., et al. (2000). Prolonged survival and tissue trafficking following adoptive transfer of CD4 z gene-modified autologous CD4 + and CD8 + T ce lls in HIV-infected subjects. Blood 96, 785-793.
49. Nelson-Rees, W.A., Daniels, D.W., and Flandermeyer, R.R. (1981). Cross-contamination of cells in culture. Science 212, 446-452.
50. Palmer, L.D., Weng, N.P., Levine, B.L., et al. (1997). Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4 + and CD8 + T cells from HIVdiscordant monozygotic twins. J. Exp. Med. 185, 1381-1386.
51. Perez, E.E., Wang, J., Miller, J.C., et al. (2008). Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816.
52. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
53. Rabinovitch, P.S., June, C.H., Grossmann, A., and Ledbetter, J.A. (1986). Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J. Immunol. 137, 952-961.
54. Rapoport, A.P., Levine, B.L., Badros, A., et al. (2004). Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant. 33, 53-60.
55. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., et al. (2009). Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N. Engl. J. Med. 361, 2209-2220.
56. Riley, J.L., Carroll, R.G., Levine, B.L., et al. (1997). Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J. Immunol. 158, 5545-5553.
57. Roessig C.,Scherer S.P.,Baer A.,et al., 2002, Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann. Hematol. 81 Suppl, 2, S42-S43.
58. Romeo, C., and Seed, B. (1991). Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037-1046.
59. Scholler, J., Brady, T., Binder-Scholl, G., et al. (2012). Decadelong safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132Ra53.
60. Storb, R., Deeg, H.J., Whitehead, J., et al. (1986). Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314, 729-735.
61. Suhoski, M.M., Golovina, T.N., Aqui, N.A., et al. (2007). Engineering artificial antigen-presenting cells to express a diver se array of co-stimulatory molecules. Mol. Ther. 15, 981-988.
62. Tebas, P., Stein, D., Tang, W., et al. (2014). Gene editing of CCR5 in autologous CD4 T-cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910.
63. Thompson, C.B., June, C.H., Sullivan, K.M., and Thomas, E.D. (1984). Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2, 1116-1120.
64. Thompson, C.B., Lindsten, T., Ledbetter, J.A., et al. (1989). CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86, 1333-1337.
65. Walker, R.E., Bechtel, C.M., Natarajan, V., et al. (2000). Longterm in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96, 467-474.
66. Wang, G.P., Levine, B.L., Binder, G.K., et al. (2009). Analysis of lentiviral vector integration in HIV + study subjects receiving autologous infusions of gene modified CD4 + T cells. Mol. Ther. 17, 844-850.
67. Weng, N.P., Levine, B.L., June, C.H., and Hodes, R.J. (1995). Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. USA 92, 11091-11094.
68. Weng, N.P., Levine, B.L., June, C.H., and Hodes, R.J. (1996). Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 183, 2471-2480.